Volume 14, Number 9—September 2008
Research
Pediatric Parapneumonic Empyema, Spain
Table 1
Characteristic | Value |
---|---|
Age, mo, mean ± SD (range) | 51.8 ± 31 (2–180) |
Gender ratio, M/F | 1.06 |
Underlying disease, %† | 4 |
Oral antimicrobial drugs before admission, %‡ | 29 |
Antimicrobial drug free before thoracocentesis, %§ | 23 |
PCV7 >1 dose, % | 31 |
Referral, % | 38 |
*PPE, pediatric parapneumonic empyema; PCV7, 7-valent pneumococcal conjugate vaccine.
†Underlying disease included (no. patients): lymphoma (2), congenital heart disease (2), mild psychomotor retardation (2), varicella zoster infection (2) and genetic disease (1).
‡Median duration: 3 d, range 1–17 d.
§100/147 children who had not been treated with oral antimicrobial drug therapy before admission received intravenous antimicrobial drug treatment before thoracocentesis for a median of 2 d (range 1–10 d).
Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.